<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982173</url>
  </required_header>
  <id_info>
    <org_study_id>2018-003115-21</org_study_id>
    <secondary_id>2018/2798</secondary_id>
    <nct_id>NCT03982173</nct_id>
  </id_info>
  <brief_title>Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors</brief_title>
  <acronym>MATILDA</acronym>
  <official_title>A Phase II Whole Exome Secquencing-based Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy (as measured by overall tumour response rate) of the combination of&#xD;
      durvalumab and tremelimumab when given to previously treated patients with solid tumors&#xD;
      harboring a high mutational load.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumour response rate</measure>
    <time_frame>at 12 weeks</time_frame>
    <description>measured according to RECIST (version 1.1)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>Stomach Adenocarcinoma</condition>
  <condition>Esophageal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>previously treated patients with solid tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>previously treated patients with solid tumors harboring a high mutational load.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>tremelimumab 75mg</description>
    <arm_group_label>previously treated patients with solid tumors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab 1500mg</description>
    <arm_group_label>previously treated patients with solid tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained from the subject prior to performing any&#xD;
             protocol-related procedures, including screening evaluations&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Histologically confirmed diagnosis of metastatic colorectal adenocarcinoma (without&#xD;
             microsatellite instability (not MSI), triple negative breast cancer, prostate&#xD;
             adenocarcinoma and stomach and esophageal gastric junction adenocarcinoma.&#xD;
&#xD;
          4. Metastatic disease or unresectable locally advanced malignancy that is resistant or&#xD;
             refractory to standard therapy or for which standard therapy does not exist or is not&#xD;
             considered appropriate by the Investigator&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no&#xD;
             deterioration over the 2 weeks prior to starting dose&#xD;
&#xD;
          6. Estimated life expectancy of greater than 12 weeks&#xD;
&#xD;
          7. Detection of ≥ 5 somatic mutations per megabase measured by whole exome sequencing in&#xD;
             a tumor sample of the patient taken after completing last therapy, within a molecular&#xD;
             screening program (this data must been known before screening period)&#xD;
&#xD;
          8. Total bilirubin ≤ 1.5 ULN (for subjects with documented/suspected Gilbert's disease,&#xD;
             bilirubin ≤ 3 ×ULN), ALT or AST ≤ 2.5 ULN (for subjects with liver metastases, AST or&#xD;
             ALT ≤ 5 × ULN), albumin ≥ 30 g/L&#xD;
&#xD;
          9. Haemoglobin &gt; 9 g/dL, neutrophils &gt; 1500/mm3, platelets &gt; 100,000/mm3&#xD;
&#xD;
         10. Serum creatinine CL&gt;40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault&#xD;
             1976) or by 24-hour urine collection for determination of creatinine clearance.&#xD;
&#xD;
         11. At least one lesion, not previously irradiated, which can be measured at baseline as&#xD;
             ≥10 mm in the longest diameter (except lymph nodes which must have short axis ≥ 15 mm)&#xD;
             with computed tomography (CT) or magnetic resonance imaging (MRI) and suitable for&#xD;
             repeated assessment according to Response Evaluation Criteria in Solid Tumors (RECIST)&#xD;
             guidelines v1.1.&#xD;
&#xD;
         12. Females of childbearing potential who are sexually active with a non-sterilized male&#xD;
             partner must use at least 1 highly effective method of contraception, from screening,&#xD;
             and must agree to continue using such precautions for 180 days after the final dose of&#xD;
             durvalumab and tremelimumab or 90 days after the last dose of durvalumab monotherapy,&#xD;
             whichever is the longer time period; cessation of birth control after this point&#xD;
             should be discussed with a responsible physician. Male partners of a female subject&#xD;
             must use male condom plus spermicide throughout this period. Not engaging in sexual&#xD;
             activity for the total duration of the drug treatment and the drug washout period is&#xD;
             an acceptable practice; however, periodic abstinence, the rhythm method, and the&#xD;
             withdrawal method are not acceptable methods of birth control.&#xD;
&#xD;
               1. Females of childbearing potential are defined as those who are not surgically&#xD;
                  sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete&#xD;
                  hysterectomy) or postmenopausal (defined as 12 months with no menses without an&#xD;
                  alternative medical cause)&#xD;
&#xD;
               2. Subjects must use at least one method of contraception highly effective, such as&#xD;
                  Copper T intrauterine device, Levonorgestrel-releasing intrauterine system (eg,&#xD;
                  Mirena® ) a Etonogestrel implants; eg, Implanon or Norplan, Intravaginal device;&#xD;
                  eg, ethinylestradiol and etonogestrel, Medroxyprogesterone injection:&#xD;
                  DepoProvera, Normal and low dose combined oral contraceptive pil,&#xD;
                  Norelgestromin/ethinylestradiol transdermal system or use of Cerazette&#xD;
                  (desogestrel)&#xD;
&#xD;
               3. Female subjects should also refrain from breastfeeding throughout this period&#xD;
&#xD;
               4. Females of childbearing potential must have a negative serum pregnancy test&#xD;
                  result within 3 days prior to initiation of study drugs Nonsterilized males who&#xD;
                  are sexually active with a female partner of childbearing potential must use a&#xD;
                  male condom with spermicide for 180 days after the final dose of durvalumab and&#xD;
                  tremelimumab or 90 days after the last dose of durvalumab monotherapy, whichever&#xD;
                  is the longer time period. Female partners of a male subject must use a highly&#xD;
                  effective method of contraception throughout this period. Not engaging insexual&#xD;
                  activity is an acceptable practice; however, occasional abstinence, the rhythm&#xD;
                  method, and the withdrawal method are not acceptable methods of contraception.&#xD;
                  Male subjects should refrain from sperm donation and female subjects should&#xD;
                  refrain from oocyte donation throughout this period.&#xD;
&#xD;
         13. Absence of any psychological, familial or geographical condition potentially hampering&#xD;
             compliance with the study protocol and follow-up schedule; those conditions should be&#xD;
             discussed with the patient before inclusion in the trial&#xD;
&#xD;
         14. Patient must be affiliated to a social security system or beneficiary of the same&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in another clinical study with an investigational product during the&#xD;
             last 4 weeks (excepting noninterventional clinical studies)&#xD;
&#xD;
          2. Concurrent enrolment in another clinical study (with an investigational product),&#xD;
             unless it is an non-interventional clinical study&#xD;
&#xD;
          3. Any previous treatment with immunotherapy including (but not limited to) compounds&#xD;
             such as, PD1 or PD-L1 inhibitors, including durvalumab or an anti-CTLA4 inhibitors,&#xD;
             including tremelimumab.&#xD;
&#xD;
          4. Previous exposure to anti oncogenic vaccines, such as Sipuleucel - T is not allowed&#xD;
&#xD;
          5. History of another primary malignancy except for:&#xD;
&#xD;
               1. Malignancy treated with curative intent and with no known active disease ≥5 years&#xD;
                  before the first dose of study drug and of low potential risk for recurrence&#xD;
&#xD;
               2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease&#xD;
&#xD;
               3. Adequately treated carcinoma in situ without evidence of disease eg, cervical&#xD;
                  cancer in situ.&#xD;
&#xD;
          6. Receipt of the last dose of anti-cancer therapy (chemotherapy, endocrine therapy,&#xD;
             targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other&#xD;
             investigational agent) 28 days prior to the first dose of study drug. A shorter&#xD;
             duration of five half times may be considered after Sponsor approval, for&#xD;
             patientstreated with non-cytotoxic drugs). (If sufficient wash-out time has not&#xD;
             occurred due to the schedule or PK properties of an agent, a longer wash-out period&#xD;
             may be required.)&#xD;
&#xD;
          7. Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of durvalumab or tremelimumab. The following are exceptions to this criterion:&#xD;
&#xD;
               1. Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra&#xD;
                  articular injection)&#xD;
&#xD;
               2. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of&#xD;
                  prednisone or its equivalent&#xD;
&#xD;
               3. Steroids as premedication for hypersensitivity reactions (eg, CT scan&#xD;
                  premedication)&#xD;
&#xD;
          8. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the&#xD;
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion&#xD;
             criteria&#xD;
&#xD;
               1. Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after&#xD;
                  consultation with the Study Physician.&#xD;
&#xD;
               2. Patients with irreversible toxicity not reasonably expected to be exacerbated by&#xD;
                  treatment with durvalumab or tremelimumab may be included only after consultation&#xD;
                  with the Study Physician.&#xD;
&#xD;
          9. Any concurrent chemotherapy, IMP, biologic, or hormonal therapy for cancer treatment.&#xD;
             Concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone&#xD;
             replacement therapy) is acceptable.&#xD;
&#xD;
         10. Major surgical procedure (as defined by the Investigator) within 28 days prior to the&#xD;
             first dose of IMP. Note: Local surgery of isolated lesions for palliative intent is&#xD;
             acceptable.&#xD;
&#xD;
         11. Active or prior documented autoimmune or inflammatory disorders (including&#xD;
             inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the&#xD;
             exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or&#xD;
             Wegener syndrome [granulomatosis with polyangitis, Graves' disease, rheumatoid&#xD;
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this&#xD;
             criterion:&#xD;
&#xD;
               1. Patients with vitiligo or alopecia&#xD;
&#xD;
               2. Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on&#xD;
                  hormonere placement&#xD;
&#xD;
               3. Any chronic skin condition that does not require systemic therapy&#xD;
&#xD;
               4. Patients without active disease in the last 5 years may be included but only&#xD;
                  after consultation with the study physician&#xD;
&#xD;
               5. Patients with celiac disease controlled by diet alone&#xD;
&#xD;
         12. History of primary immunodeficiency&#xD;
&#xD;
         13. History of allogeneic organ transplant&#xD;
&#xD;
         14. Uncontrolled intercurrent illness, including but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic&#xD;
             gastrointestinal conditions associated with diarrhea, or psychiatric illness/social&#xD;
             situations that would limit compliance with study requirement, substantially increase&#xD;
             risk of incurring AEs or compromise the ability of the patient to give written&#xD;
             informed consent&#xD;
&#xD;
         15. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required&#xD;
             steroid treatment, or any evidence of clinically active interstitial lung disease&#xD;
&#xD;
         16. Active infection including tuberculosis (clinical evaluation including clinical&#xD;
             history, physical examination and radiographic findings, and TB testing in line with&#xD;
             local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result),&#xD;
             hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients&#xD;
             with a past or resolved HBV infection (defined as the presence of hepatitis B core&#xD;
             antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for&#xD;
             hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative&#xD;
             for HCV RNA.&#xD;
&#xD;
         17. History of leptomeningeal carcinomatosis&#xD;
&#xD;
         18. Subjects with uncontrolled seizures&#xD;
&#xD;
         19. Brain metastases or spinal cord compression unless the patient is stable&#xD;
             (asymptomatic; no evidence of new or emerging brain metastases; and stable and off&#xD;
             steroids for at least 28 days prior to start of study treatment). Following&#xD;
             radiotherapy and/or surgery of the brain metastases patients must wait 4 weeks&#xD;
             following the intervention and before randomisation with imaging to confirm stability.&#xD;
&#xD;
         20. Receipt of live attenuated vaccine within 30 days prior to the first dose of IMPs.&#xD;
             Note: Patients, if enrolled, should not receive live vaccine whilst receiving IMPs and&#xD;
             up to 30 days after the last dose of IMPs.&#xD;
&#xD;
         21. Female patients who are pregnant or breastfeeding or male or female patients of&#xD;
             reproductive potential who are not willing to employ effective birth control from&#xD;
             screening to 180 days after the last dose of durvalumab + tremelimumab combination&#xD;
             therapy or 90 days after the last dose of durvalumab monotherapy or confirmation of PD&#xD;
             and investigator determination that the subject is no longer benefiting from treatment&#xD;
             with durvalumab + tremelimumab whichever is the longer time period.&#xD;
&#xD;
         22. Known allergy or hypersensitivity to any of the study drugs or any of the study drug&#xD;
             excipients.&#xD;
&#xD;
         23. Any condition that, in the opinion of the investigator, would interfere with&#xD;
             evaluation of study treatment or interpretation of patient safety or study results&#xD;
&#xD;
         24. Patient under guardianship or deprived of his liberty by a judicial or administrative&#xD;
             decision or incapable of giving its consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 7, 2019</study_first_submitted>
  <study_first_submitted_qc>June 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>June 7, 2019</last_update_submitted>
  <last_update_submitted_qc>June 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

